Back to Search
Start Over
Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study.
- Source :
-
Bioanalysis [Bioanalysis] 2018 Jun 01; Vol. 10 (11), pp. 863-875. Date of Electronic Publication: 2018 Jun 04. - Publication Year :
- 2018
-
Abstract
- Aim: Hemay005 is a novel small-molecule inhibitor of phosphodiesterase-4 developed for the treatment of psoriasis. Measurement of Hemay005 in biological samples is critical for evaluation of its pharmacokinetics in clinical studies. Methodology & results: Plasma and urine samples were extracted and then chromatographed on an Acquity UPLC HSS T3 column with a gradient elution. Detection was performed on a Xevo TQ-S tandem mass spectrometer using negative ESI.<br />Conclusion: For the first time, a sensitive and robust ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the quantitative determination of Hemay005 in human plasma and urine, and it was successfully applied to evaluate the pharmacokinetics of Hemay005 in healthy subjects in a first-in-human study.
- Subjects :
- Acetamides pharmacokinetics
Analytic Sample Preparation Methods
Humans
Phosphodiesterase 4 Inhibitors blood
Phosphodiesterase 4 Inhibitors pharmacokinetics
Phosphodiesterase 4 Inhibitors urine
Pyrroles pharmacokinetics
Reproducibility of Results
Thiophenes pharmacokinetics
Acetamides blood
Acetamides urine
Blood Chemical Analysis methods
Chromatography, High Pressure Liquid methods
Pyrroles blood
Pyrroles urine
Tandem Mass Spectrometry methods
Thiophenes blood
Thiophenes urine
Urinalysis methods
Subjects
Details
- Language :
- English
- ISSN :
- 1757-6199
- Volume :
- 10
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Bioanalysis
- Publication Type :
- Academic Journal
- Accession number :
- 29863892
- Full Text :
- https://doi.org/10.4155/bio-2018-0004